Member Info for emptyend

Don’t disagree with that at all!!

But it wasn’t correct to claim that 16p has “gone”……even if it will (most probably) later today.

Calm down and make yourself a nice cup of tea. 🙄

Only 1,055 shares traded and doubtless lots more available…..

……17 patients and six partial responses?? ………well……..🤔😏🤫😎

“ they still need security before they jump in.”

……..not necessarily. They might well be risk averse - most people and companies are. But the flipside of risk is opportunity. And, in a competitive market, it can be a bigger risk to let competitors steal promising IP from under your nose, than to leap in and buy it yourself.

Like chillpill I also expect an outright bid - and at a huge premium. There are a host of applications for Scancell’s technology in a number of the big pharma companies - and I expect extremely competitive terms.

Until the method of funding for the new trials has been announced, they wouldn’t be so silly as to unnecessarily preclude options that may be available. But the intention is very clear indeed……

Yes Burble. There is clear evidence that the upcoming trials will produce positive outcomes - and also that they have identified the company’s USP compared to the competition.

Note also the throwaway point about prior disposal experience. 😏

The key word in this release is in the comments of the appointee: it is “pivotal” 🤫

Correct!

I have emailed the PR company who, if they didn’t cause the error, should surely have spotted it! Sloppy “holiday relief” error? 🤨

Fortunately it isn’t a needle-mover RNS - but it does seem to be an appointment that has long been wanted by management “when circumstances allow”……which is also intriguing.

There is obviously a line of stock from the placing in December. Would be nice if someone (Vulpes?) took it all out……

You can ignore the analyst estimate. They will soon be changing/increasing it as the chance of successful development rises.. It could easily be 60-70p when nexy published.

I suspect that “barrier” will be cleared by a big corporate deal next year. Meantime the data from two trials etc could lead to a six-fold increase or so, in my view. That would basically be a derisking of the chances of successful development of iSCIB1+ and Modi-1, plus Modi-2 heading into the clinic.

I don’t think over-enthusiasm helps, especially on matters of timing. Things always take longer than optimists like to hope.

BUT that doesn’t mean events won’t occur to change matters literally overnight. My own thoughts are that I can see a reasonable path to £1+ per share. But I don’t rule out significantly more if it turns out Lindy has made a game-changing, patent-protected breakthrough that offers superior lower-risk patient outcomes and at lower cost.

There is no law of gravity that means share prices can’t keep going up for many years - ask Bezos and Musk…….

….ps…..my mistake…….Tesla actually had two stock splits……so one share worth $20 in 2010 would be worth #3,300 today, even after the fall of the last year or so. So buying my car instead cost me the potential to make over £10 million at present values.

My point is that growth company equities have an unbounded upside. Who knows, even Inanaco’s £8 a share may turn out to be conservative?

Tesla had a stock split. 1 for 4 or 5.

Still a good sell though, as they had become ridiculously overvalued.

However, I mention it because I did actually consider investing in Tesla stock in 2010 - but instead bought a car. Had I invested in Tesla stock instead of buying the car, my holding would have been worth about $10 million at the peak, if I’d had the balls to hold it all the time (which I wouldn’t have done).

Waiting for share prices to drop back only works if they do. It didn’t work for me in Tesla and it may not work for you here - though you seem not to mind, which is fine.

Kash’s line of thought is entirely reasonable - and it is what fund managers depend on to provide liquidity in AIM stocks……create a 50% “profit” in a couple of weeks and you can guarantee some will take it.

…….but those who do may face the shares they sold going on to many multiples of the price they sold at. Personally, I only take equity risk in any size if I expect to make many multiples of my investment.

Think of the Tesla shareholders who sold at $20 in 2010 and then saw it go on to clear $2000 easily….. If you are cool with having made 30-40% when selling at $20, you’re operating in a different way to me.

I’m pretty sure that I suggested (earlier this year when some were whingeing at the lack of updates, anodyne language and apparent “nothing happening”) that things would be going on under the surface - perhaps even including new discoveries or new patents, as was the case when they first discovered Moditope and went into “silent mode”.

Pretty soon we’ll be beyond the “nod and wink” stage and into some solid data…..

Indeed. The handy SCLP Media tab above takes you straight to the most recent interview, and the relevant bit is the answer to the last question…..”I think I’m there” etc…..

Not that strange. It is all about somebody (singular or plural) seeking to accumulate a large block of shares at the lowest possible price. Hence coming off the bid completely on down days for the market and instead sweeping up whatever is made available on the offer.

….unlikely, since I was asking if anyone could see it……because I can’t 🙄